AstraZeneca
BMS signs cancer deal
May 28, 2014Research and Development, Sales and Marketing ASCO, AstraZeneca, BMS, Cancer, Merck, Roche, cytomx, oncology
Bristol-Myers Squibb has partnered with CytomX Therapeutics to discover and develop new immuno-oncology candidates using the latter’s Probody Platform technology. …
Pfizer admits AstraZeneca defeat
May 27, 2014Manufacturing and Production, Research and Development, Sales and Marketing AZ, AstraZeneca, Pfizer, Read, buyout, merger
Pfizer has acknowledged that it will not make an offer for AstraZeneca following the firms’ failure to agree a price …
AstraZeneca rejects Pfizer’s ‘final offer’
May 19, 2014Medical Communications, Research and Development, Sales and Marketing AstraZeneca, MPs, Pfizer, R&D, UK, science, takeover
AstraZeneca has this morning rejected a new bid from Pfizer that could have seen the US giant pay £69 billion …
Science left behind in Pfizer-AstraZeneca saga
May 18, 2014Medical Communications, Research and Development, Sales and Marketing AstraZeneca, MPs, Pfizer, Wellcome Trust, science
With all the posturing, debates and endless comment on the commercial aspects of a $106 billion deal between Pfizer and …
AstraZeneca signs UK research deal
May 16, 2014Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cambridge, Pfizer
The UK’s Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) and AstraZeneca will join forces to help discover new …
AstraZeneca lung cancer data reveals promise
May 15, 2014Sales and Marketing ASCO, AstraZeneca, NSCLC, azd0291, lung cancer
AstraZeneca has released promising data in a lung cancer trial with one of its investigational drugs, AZD9291, which has breakthrough …
MedImmune signs Incyte oncology deal
May 15, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Incyte, MedImmune, oncology
MedImmune, the global biologics R&D arm of AstraZeneca, is to put one of its oncology immunotherapies into development in combination …
Pfizer: ‘fewer scientists’ after merger
May 14, 2014Research and Development, Sales and Marketing AstraZeneca, Pfizer, Read, Soriot, UK, Willetts, merger, takeover
Pfizer’s proposed takeover of AstraZeneca would result in there being fewer scientists from both companies in the UK than currently …
Poll: UK opposed to Pfizer takeover bid of AZ
May 13, 2014Research and Development, Sales and Marketing AstraZeneca, Cameron, Pfizer, UK, buyout, merger, research
The UK’s largest union says a new poll shows that the vast majority of the British public are against Pfizer’s …
AZ ‘consulted first’ by UK government after Pfizer bid
May 12, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, George Osborne, Pfizer, Wellcome Trust, david cameron
UK prime minister David Cameron has rejected claims that his government is prioritising discussions with Pfizer over its proposed acquisition …
Pfizer signs universities deal
May 12, 2014Research and Development, Sales and Marketing AstraZeneca, Pfizer, academics, rare diseases
Pfizer has signed a five-year research deal with several top British universities to hunt for new treatments for rare disease. …
‘Bioscience is cornerstone’ of Alderley Park
May 12, 2014Research and Development, Sales and Marketing AZ, AstraZeneca, alderley, msp, research
Manchester Science Parks (MSP), the new owners of the 400-acre Alderley Park facility, has pledged to keep its activities “at …
AstraZeneca begins lung cancer trial
May 9, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer
AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …
Pfizer will ‘suck AZ’s lifeblood’
May 7, 2014Research and Development, Sales and Marketing AstraZeneca, Pfizer, Read, Soriot, bbd, cable, merger
A former boss of AstraZeneca has warned that he fears Pfizer “will act like a praying mantis and suck the …
Pfizer appeals to UK prime minister
May 6, 2014Manufacturing and Production, Sales and Marketing AstraZeneca, Cameron, Pfizer, merger, research
Pfizer has attempted to enlist the help of UK prime minister David Cameron in its campaign to buy AstraZeneca, offering …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
